Buspirone Hydrochloride NDC 64980-654

NDC codes

FDA NDC Directory

Product NDC (as listed)64980-654Labeler and product segments. Claims need a package NDC.

Product NDC at billing width64980-0654Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
64980-654-06	64980065406	60 TABLET in 1 BOTTLE (64980-654-06)Marketed from Feb 27, 2026
64980-654-50	64980065450	500 TABLET in 1 BOTTLE (64980-654-50)Marketed from Feb 27, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Buspirone Hydrochloride
Generic name (nonproprietary): buspirone hydrochloride
Active ingredients: Buspirone hydrochloride — 30 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Rising Pharma Holdings, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 075413
Marketing start: Feb 27, 2026
Listing expires: Dec 31, 2027
Identifiers: Product ID 64980-654_66cf8d73-ea13-47fe-be0f-45edd9101d2dSPL ID 66cf8d73-ea13-47fe-be0f-45edd9101d2dSPL set ID b9aa144c-cb36-4069-9eaa-7c150298cdd7RxCUI 866018, 866083, 866090, 866094, 866111UNII 207LT9J9OC

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N464980065406 followed by a unit qualifier and the quantity

Package 64980-0654-06. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 2, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these st…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 075413

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 075413
Product	Strength	Form · route	Labeler	Product NDC
Buspirone Hydrochloride	Buspirone hydrochloride 10 mg/1	TabletOral	Rising Pharma Holdings, Inc.	64980-652
Buspirone Hydrochloride	Buspirone hydrochloride 5 mg/1	TabletOral	Rising Pharma Holdings, Inc.	64980-650
Buspirone Hydrochloride	Buspirone hydrochloride 7.5 mg/1	TabletOral	Rising Pharma Holdings, Inc.	64980-651
Buspirone Hydrochloride	Buspirone hydrochloride 15 mg/1	TabletOral	Rising Pharma Holdings, Inc.	64980-653